| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
CREBBP mutations in relapsed acute lymphoblastic leukaemia.
|
Nature
|
2011
|
3.72
|
|
2
|
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
|
J Clin Oncol
|
2006
|
2.35
|
|
3
|
Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer.
|
J Clin Oncol
|
2010
|
2.07
|
|
4
|
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.
|
Clin Cancer Res
|
2007
|
2.07
|
|
5
|
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
|
J Clin Oncol
|
2007
|
2.01
|
|
6
|
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
|
Blood
|
2013
|
1.87
|
|
7
|
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
|
J Clin Oncol
|
2008
|
1.84
|
|
8
|
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.
|
J Clin Oncol
|
2008
|
1.71
|
|
9
|
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.
|
J Clin Oncol
|
2009
|
1.71
|
|
10
|
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.
|
Cancer Res
|
2004
|
1.55
|
|
11
|
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
|
J Clin Oncol
|
2011
|
1.52
|
|
12
|
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
|
J Clin Oncol
|
2002
|
1.52
|
|
13
|
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.
|
Mol Cancer Ther
|
2002
|
1.51
|
|
14
|
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.
|
J Natl Cancer Inst
|
2006
|
1.48
|
|
15
|
Interaction of imatinib with human organic ion carriers.
|
Clin Cancer Res
|
2008
|
1.47
|
|
16
|
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2006
|
1.47
|
|
17
|
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
|
Cancer Biol Ther
|
2007
|
1.47
|
|
18
|
Irinotecan pathway genotype analysis to predict pharmacokinetics.
|
Clin Cancer Res
|
2003
|
1.42
|
|
19
|
Ductal access for prevention and therapy of mammary tumors.
|
Cancer Res
|
2006
|
1.38
|
|
20
|
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.
|
J Natl Cancer Inst
|
2006
|
1.38
|
|
21
|
Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.
|
Clin Cancer Res
|
2009
|
1.35
|
|
22
|
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors.
|
J Clin Oncol
|
2008
|
1.30
|
|
23
|
Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.
|
J Clin Oncol
|
2005
|
1.25
|
|
24
|
Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.
|
Clin Cancer Res
|
2012
|
1.24
|
|
25
|
Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
|
J Natl Cancer Inst
|
2011
|
1.23
|
|
26
|
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies.
|
J Clin Oncol
|
2005
|
1.22
|
|
27
|
Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2003
|
1.16
|
|
28
|
Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study.
|
Neuro Oncol
|
2005
|
1.16
|
|
29
|
Activated pregnenolone X-receptor is a target for ketoconazole and its analogs.
|
Clin Cancer Res
|
2007
|
1.12
|
|
30
|
Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2010
|
1.10
|
|
31
|
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
|
Cancer Chemother Pharmacol
|
2007
|
1.10
|
|
32
|
Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients.
|
Invest New Drugs
|
2006
|
1.08
|
|
33
|
A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma.
|
J Pharm Biomed Anal
|
2006
|
1.07
|
|
34
|
Simultaneous determination of steroid composition of human testicular fluid using liquid chromatography tandem mass spectrometry.
|
Steroids
|
2004
|
1.07
|
|
35
|
Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.
|
Clin Cancer Res
|
2012
|
1.06
|
|
36
|
Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2004
|
1.03
|
|
37
|
Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51.
|
PLoS One
|
2013
|
1.03
|
|
38
|
A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors.
|
Clin Cancer Res
|
2009
|
1.02
|
|
39
|
Pharmacokinetics and toxicity of weekly docetaxel in older patients.
|
Clin Cancer Res
|
2006
|
1.02
|
|
40
|
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
|
Clin Cancer Res
|
2005
|
1.01
|
|
41
|
Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.
|
Am J Clin Oncol
|
2006
|
1.01
|
|
42
|
Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.
|
Clin Pharmacol Ther
|
2003
|
0.99
|
|
43
|
A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors.
|
Clin Cancer Res
|
2005
|
0.99
|
|
44
|
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.
|
Clin Pharmacol Ther
|
2006
|
0.99
|
|
45
|
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
|
Mol Cancer Ther
|
2008
|
0.98
|
|
46
|
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
|
Clin Cancer Res
|
2006
|
0.97
|
|
47
|
Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide.
|
Clin Cancer Res
|
2013
|
0.97
|
|
48
|
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
|
Clin Pharmacol Ther
|
2004
|
0.97
|
|
49
|
Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models.
|
Cancer Biol Ther
|
2007
|
0.95
|
|
50
|
Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2002
|
0.95
|
|
51
|
Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile.
|
Clin Cancer Res
|
2003
|
0.94
|
|
52
|
Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.
|
Pharmacogenomics
|
2011
|
0.93
|
|
53
|
A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies.
|
Invest New Drugs
|
2006
|
0.93
|
|
54
|
Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study.
|
Pharmacotherapy
|
2004
|
0.93
|
|
55
|
Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2008
|
0.93
|
|
56
|
Ontogeny and sorafenib metabolism.
|
Clin Cancer Res
|
2012
|
0.92
|
|
57
|
Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy.
|
Clin Cancer Res
|
2012
|
0.90
|
|
58
|
Marginal increase of sunitinib exposure by grapefruit juice.
|
Cancer Chemother Pharmacol
|
2010
|
0.89
|
|
59
|
Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib.
|
Clin Cancer Res
|
2007
|
0.89
|
|
60
|
Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.
|
Clin Cancer Res
|
2013
|
0.88
|
|
61
|
Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.
|
Clin Cancer Res
|
2003
|
0.88
|
|
62
|
Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.
|
Clin Cancer Res
|
2005
|
0.88
|
|
63
|
Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF.
|
Leuk Res
|
2010
|
0.87
|
|
64
|
Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer.
|
Breast Cancer Res Treat
|
2011
|
0.86
|
|
65
|
Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
|
Clin Cancer Res
|
2008
|
0.86
|
|
66
|
Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report.
|
Oncology (Williston Park)
|
2003
|
0.85
|
|
67
|
Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy?
|
J Clin Oncol
|
2005
|
0.85
|
|
68
|
Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches.
|
Clin Pharmacol Ther
|
2003
|
0.84
|
|
69
|
Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2005
|
0.84
|
|
70
|
Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).
|
Clin Cancer Res
|
2013
|
0.82
|
|
71
|
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma for clinical pharmacology studies.
|
J Pharm Biomed Anal
|
2006
|
0.82
|
|
72
|
Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer.
|
Clin Cancer Res
|
2006
|
0.82
|
|
73
|
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
|
J Clin Oncol
|
2002
|
0.81
|
|
74
|
In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent.
|
Clin Cancer Res
|
2005
|
0.81
|
|
75
|
Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
|
Clin Cancer Res
|
2006
|
0.80
|
|
76
|
Determination of fraction unbound docetaxel using microequilibrium dialysis.
|
Anal Biochem
|
2004
|
0.80
|
|
77
|
Inhibition of OCTN2-mediated transport of carnitine by etoposide.
|
Mol Cancer Ther
|
2012
|
0.80
|
|
78
|
Validation and implementation of a method for determination of bryostatin 1 in human plasma by using liquid chromatography/tandem mass spectrometry.
|
Anal Biochem
|
2005
|
0.80
|
|
79
|
Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.
|
J Clin Oncol
|
2002
|
0.79
|
|
80
|
Distribution of paclitaxel in plasma and cerebrospinal fluid.
|
Anticancer Drugs
|
2003
|
0.79
|
|
81
|
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate dimethyl benzoylphenylurea (BPU) and its five metabolites in human plasma and urine for clinical pharmacology studies.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2005
|
0.78
|
|
82
|
A method for determination of dimethyl benzoylphenyl urea (BPU) in human plasma by using LC/UV.
|
Biomed Chromatogr
|
2004
|
0.78
|
|
83
|
A sensitive method for determination of COL-3, a chemically modified tetracycline, in human plasma using high-performance liquid chromatography and ultraviolet detection.
|
J Pharm Biomed Anal
|
2004
|
0.78
|
|
84
|
A rapid and sensitive method for determination of dimethyl benzoylphenyl urea in human plasma by using LC/MS/MS.
|
J Pharm Biomed Anal
|
2003
|
0.78
|
|
85
|
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.
|
Invest New Drugs
|
2010
|
0.77
|
|
86
|
Predicting vinorelbine disposition and toxicity: does BSA provide more than a "bad statistical association"?
|
J Clin Oncol
|
2006
|
0.77
|
|
87
|
Limited cerebrospinal fluid penetration of docetaxel.
|
Anticancer Drugs
|
2004
|
0.76
|
|
88
|
Alternative formulations of sorafenib for use in children.
|
Pediatr Blood Cancer
|
2013
|
0.75
|
|
89
|
Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours.
|
Eur J Cancer
|
2006
|
0.75
|